Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates

Juno Therapeutics to Be Acquired by Celgene Corporation

Skadden is advising Juno Therapeutics, Inc. on its acquisition by Celgene Corporation valuing Juno at over $11 billion.

BACK TO TOP